Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program. Chief Executive Officer Brian Culley said the company’s strategy, which it calls “Lineage 3.0,” centers on using its AlloSCOPE manufacturing platform to develop allogeneic, or off-the-shelf, cell therapies that can be produced consistently at scale. Culley said the company aims to target indications where small initial trials could generate meaningful treatment signals and where Lineage can retain improved economics through internal development or partnerships.

Culley said Lineage has established a two-tier current good manufacturing practice banking and production system that it believes can produce millions of vials of a product candidate. Material from those banks has been cleared by the FDA and used in the OpRegen clinical trial, he said. The company believes the platform can support production costs in the hundreds of dollars per dose, compared with potentially much higher costs for autologous therapies. Culley emphasized that cell-therapy manufacturing requires reproducibility, purity, potency and scalability, and said changes to a production process after early clinical trials can create regulatory and comparability risks. During the question-and-answer session, Culley declined to provide more detailed information on the vessel sizes used in the company’s Type 1 diabetes manufacturing work, citing the proprietary nature of the process. He said Lineage’s approach is to establish a scalable manufacturing process early rather than modify it later after clinical data are obtained.

Lineage’s wholly owned COR1 program is being developed as a corneal endothelial cell therapy for Fuchs’ dystrophy and other corneal endothelial diseases. The company began evaluating the program in the second quarter of 2025 and initiated laboratory work in the third quarter of that year. According to Culley, Lineage has applied its AlloSCOPE 5D technology to expand precursor cells in bioreactors and differentiate them into corneal endothelial cells. Preclinical in vivo testing is expected to begin imminently, with initial internal animal data targeted by year-end. The company plans to evaluate whether its cells perform at least as well as cadaver-derived cells in established efficacy models. Culley said the program addresses supply and shelf-life limitations in donor-derived corneal transplants. He cited an estimate of one donor for every 70 diseased eyes globally and noted that donor-derived material must be used promptly rather than cryopreserved.